Cited by 610

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol

Russo, Ethan, Guy, Geoffrey W.·2006·Medical Hypotheses

DOI 10.1016/j.mehy.2005.08.026

Open this paper in CoChat — free account

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.mehy.2005.08.026

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cannabidiol and (−)Δ 9 -tetrahydrocannabinol are neuroprotective antioxidants
Hampson, A. J., Grimaldi, M., Axelrod, J., & Wink, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8268 · Cited by 850
Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial
Zajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A., & Thompson, A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14738-1 · Cited by 827
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis
Rog, D. J., Nurmikko, T. J., Friede, T., & Young, C. A. (2005) · Neurology · doi:10.1212/01.wnl.0000176753.45410.8b · Cited by 679
Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease
Lastres-Becker, I., Molina-Holgado, F., Ramos, J. A., Mechoulam, R., & Fernández-Ruiz, J. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.11.009 · Cited by 407
Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial
Berman, J. S., Symonds, C., & Birch, R. (2004) · Pain · doi:10.1016/j.pain.2004.09.013 · Cited by 362
Neuroprotective effect of cannabidiol, a non‐psychoactive component from Cannabis sativa, on β‐amyloid‐induced toxicity in PC12 cells
Iuvone, T., Esposito, G., Esposito, R., Santamaria, R., Di Rosa, M., & Izzo, A. A. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2003.02327.x · Cited by 361
Cannabis and Cannabis Extracts: Greater Than the Sum of Their Parts?
McPartland, J. M., & Russo, E. B. (2001) · Journal of Cannabis Therapeutics · doi:10.1300/j175v01n03_08 · Cited by 321
Self-citation
Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 ‘N of 1’ studies
Notcutt, W., Price, M., Miller, R., Newport, S., Phillips, C., Simmons, S., & Sansom, C. (2004) · Anaesthesia · doi:10.1111/j.1365-2044.2004.03674.x · Cited by 305
Delta 9-Tetrahydrocannabinol (THC) is Effective in the Treatment of Tics in Tourette Syndrome: a 6-Week Randomized Trial
Muller-Vahl, K. R., Schneider, U., Prevedel, H., Theloe, K., Kolbe, H., Daldrup, T., & Emrich, H. M. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0417 · Cited by 270
Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice
Moreira, F. A., & Guimarães, F. S. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.02.040 · Cited by 206

Show all 11 references

The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.
Russo, E. B. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01238.x · Cited by 1,535
Self-citation
Efficacy of acetylcholinesterase inhibitors in Alzheimer’s disease.
Marucci, G., Buccioni, M., Ben, D. D., Lambertucci, C., Volpini, R., & Amenta, F. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108352 · Cited by 1,147
Human Cannabinoid Pharmacokinetics
Huestis, M. A. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790152 · Cited by 1,102
Effects of cannabinoids and cannabinoid‐enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes
De Petrocellis, L., Ligresti, A., Moriello, A. S., Allarà, M., Bisogno, T., Petrosino, S., Stott, C. G., & Di Marzo, V. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01166.x · Cited by 946
The pharmacokinetics and the pharmacodynamics of cannabinoids
Lucas, C. J., Galettis, P., & Schneider, J. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13710 · Cited by 724
Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients with Intractable Cancer-Related Pain
Johnson, J. R., Burnell-Nugent, M., Lossignol, D., Ganae-Motan, E. D., Potts, R., & Fallon, M. T. (2010) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2009.06.008 · Cited by 622
Cannabidiol (CBD) and its analogs: a review of their effects on inflammation.
Burstein, S. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.01.059 · Cited by 573
Cannabidiol—recent advances
Mechoulam, R., Peters, M., Murillo‐Rodriguez, E., & Hanuš, L. O. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790147 · Cited by 515
A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis: Sativex for refractory spasticity in MS
Novotna, A., Mares, J., Ratcliffe, S., Novakova, I., Vachova, M., Zapletalova, O., Gasperini, C., Pozzilli, C., Cefaro, L., Comi, G., et al. (2011) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03328.x · Cited by 475
Evolution and classification of Cannabis sativa (marijuana, hemp) in relation to human utilization.
Small, E. (2015) · The Botanical Review · doi:10.1007/s12229-015-9157-3 · Cited by 461
Cannabidiol, neuroprotection and neuropsychiatric disorders
Campos, A. C., Fogaça, M. V., Sonego, A. B., & Guimarães, F. S. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.01.033 · Cited by 446
Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action
Zuardi, A. W. (2008) · Revista Brasileira de Psiquiatria · doi:10.1590/s1516-44462008000300015 · Cited by 421
The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain
Costa, B., Trovato, A. E., Comelli, F., Giagnoni, G., & Colleoni, M. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.11.006 · Cited by 395
Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats
Campos, A. C., & Guimarães, F. S. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1168-x · Cited by 364
A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain
Wilsey, B., Marcotte, T., Tsodikov, A., Millman, J., Bentley, H., Gouaux, B., & Fishman, S. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2007.12.010 · Cited by 327
Phytocannabinoids as novel therapeutic agents in {CNS} disorders.
Hill, A. J., Williams, C. M., Whalley, B. J., & Stephens, G. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.002 · Cited by 312
A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis
Collin, C., Ehler, E., Waberzinek, G., Alsindi, Z., Davies, P., Powell, K., Notcutt, W., O'Leary, C., Ratcliffe, S., Nováková, I., et al. (2010) · Neurological Research · doi:10.1179/016164109x12590518685660 · Cited by 283
Evidence for the Risks and Consequences of Adolescent Cannabis Exposure
Levine, A., Clemenza, K., Rynn, M., & Lieberman, J. (2017) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2016.12.014 · Cited by 239
Effects of cannabidiol interactions with Wnt/β-catenin pathway and PPARγ on oxidative stress and neuroinflammation in Alzheimer's disease
Vallée, A., Lecarpentier, Y., Guillevin, R., & Vallée, J.-N. (2017) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmx073 · Cited by 226
Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test
Moreira, F. A., Aguiar, D. C., & Guimarães, F. S. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.06.004 · Cited by 207
Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis.
Haney, M., Malcolm, R. J., Babalonis, S., Nuzzo, P. A., Cooper, Z. D., Bedi, G., Gray, K. M., McRae-Clark, A., Lofwall, M. R., Sparenborg, S., et al. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.367 · Cited by 206
Cannabidiol potentiates Δ9-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats
Klein, C., Karanges, E., Spiro, A., Wong, A., Spencer, J., Huynh, T., Gunasekaran, N., Karl, T., Long, L. E., Huang, X.-F., et al. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2342-0 · Cited by 206
Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis
Pamplona, F. A., da Silva, L. R., & Coan, A. C. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00759 · Cited by 190
Cannabidiol reduced the striatal atrophy caused 3‐nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1and adenosine A2Areceptors
Sagredo, O., Ramos, J. A., Decio, A., Mechoulam, R., & Fernández‐Ruiz, J. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05717.x · Cited by 147
Cannabis sativa: Much more beyond Δ9-tetrahydrocannabinol
Alves, P., Amaral, C., Teixeira, N., & Correia-da-Silva, G. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104822 · Cited by 135
Absence of Entourage: Terpenoids Commonly Found in Cannabis sativa Do Not Modulate the Functional Activity of Δ 9 -THC at Human CB 1 and CB 2 Receptors
Santiago, M., Sachdev, S., Arnold, J. C., McGregor, I. S., & Connor, M. (2019) · Cannabis & Cannabinoid Research · doi:10.1089/can.2019.0016 · Cited by 112
“…9 -THC-CBD synergy in producing analgesia was reported in an animal model of neuropathic pain 6 while in humans, CBD has been proposed to ameliorate some of the adverse psychotomimetic and anxio-genic effects of D 9 -THC. 7,8 This claim is controversial, however, with a number of contrary ﬁndings.”
Natural Phytochemicals in the Treatment and Prevention of Dementia: An Overview
Libro, R., Giacoppo, S., Soundara Rajan, T., Bramanti, P., & Mazzon, E. (2016) · Molecules · doi:10.3390/molecules21040518 · Cited by 107
Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease
Sagredo, O., Pazos, M. R., Satta, V., Ramos, J. A., Pertwee, R. G., & Fernández‐Ruiz, J. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22682 · Cited by 105
Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial
Riva, N., Mora, G., Sorarù, G., Lunetta, C., Ferraro, O. E., Falzone, Y., Leocani, L., Fazio, R., Comola, M., Comi, G., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30406-x · Cited by 104
Antihyperalgesic effect of a Cannabis sativa extract in a rat model of neuropathic pain: mechanisms involved
Comelli, F., Giagnoni, G., Bettoni, I., Colleoni, M., & Costa, B. (2008) · Phytotherapy Research · doi:10.1002/ptr.2401 · Cited by 103
A Systematic Review and Meta-Analysis of the Haemodynamic Effects of Cannabidiol
Sultan, S. R., Millar, S. A., England, T. J., & O'Sullivan, S. E. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00081 · Cited by 95
“It is suggested that CBD may have therapeutic effects in a variety of disorders including diabetes, gastrointestinal disturbances, cancer, oxidative stress, inflammation and in cardiovascular disease (Russo and Guy, 2006; Capasso et al., 2008; Zuardi, 2008; Iuvone et al., 2009; Booz, 2011).”
Sativex in the management of multiple sclerosis-related spasticity: An overview of the last decade of clinical evaluation
Giacoppo, S., Bramanti, P., & Mazzon, E. (2017) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2017.06.015 · Cited by 92
The interplay of cannabinoid and NMDA glutamate receptor systems in humans: preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects
Hallak, J. E. C., Dursun, S. M., Bosi, D. C., de Macedo, L. R. H., Machado-de-Sousa, J. P., Abrão, J., Crippa, J. A. S., McGuire, P., Krystal, J. H., Baker, G. B., et al. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.11.002 · Cited by 83
Cannabinoids: new promising agents in the treatment of neurological diseases.
Giacoppo, S., Mandolino, G., Galuppo, M., Bramanti, P., & Mazzon, E. (2014) · Molecules · doi:10.3390/molecules191118781 · Cited by 79
Sativex® and clinical–neurophysiological measures of spasticity in progressive multiple sclerosis
Leocani, L., Nuara, A., Houdayer, E., Schiavetti, I., Del Carro, U., Amadio, S., Straffi, L., Rossi, P., Martinelli, V., Vila, C., et al. (2015) · Journal of Neurology · doi:10.1007/s00415-015-7878-1 · Cited by 66
Cannabinergic Pain Medicine: A Concise Clinical Primer and Survey of Randomized-controlled Trial Results
Aggarwal, S. K. (2013) · The Clinical Journal of Pain · doi:10.1097/ajp.0b013e31824c5e4c · Cited by 62
Analgesic Effect of a Mixed T-Type Channel Inhibitor/CB2 Receptor Agonist
Gadotti, V. M., You, H., Petrov, R. R., Berger, N. D., Diaz, P., & Zamponi, G. W. (2013) · Molecular Pain · doi:10.1186/1744-8069-9-32 · Cited by 45
Daily Practice Managing Resistant Multiple Sclerosis Spasticity With Delta-9-Tetrahydrocannabinol: Cannabidiol Oromucosal Spray: A Systematic Review of Observational Studies
Akgün, K., Essner, U., Seydel, C., & Ziemssen, T. (2019) · Journal of Central Nervous System Disease · doi:10.1177/1179573519831997 · Cited by 28
Quais são e pra que servem os medicamentos à base de Cannabis?
Pamplona, F. A. (2014) · Revista da Biologia · doi:10.7594/revbio.13.01.05 · Cited by 20
“Para uma descrição detalhada do perfil farmacológica da mistura de THC/CBD sobre o THC puro, leia (Russo and Guy, 2006).”
Background

Authors: Russo, E., & Guy, G. W.
Venue: Medical Hypotheses
Publisher: Elsevier BV
Published: 2006-01
Volume: 66
Issue: 2
Pages: 234-246
ISSN: 0306-9877 (ISSN-L)
DOI: 10.1016/j.mehy.2005.08.026
OpenAlex: W2100077258
Cited by: 610
References: 11
FWCI: 10.52
Type: journal article
Language: en
Open access: closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Metadata

Record

About these checks

Data sources